Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(22):1631; doi:10.1093/jnci/dji425
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Update on Tamoxifen for Breast Cancer Prevention

The National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention study (P-1) was initiated in 1992 to investigate whether tamoxifen could prevent the development of breast cancer in women at high risk for the disease. In 1998, it was reported that women who received tamoxifen had a lower risk of breast cancer than women who received placebo; they also had a reduced risk of osteoporotic fractures and increased risks of endometrial cancer, thromboembolism, and several other undesirable side effects. In this issue, Fisher et al. (p. 1652) present updated findings . . . [Full Text of this Article]

Retinoid Resistance and Lung Carcinogenesis

Vaccination With Cetuximab Mimotopes

Lifetime Recreational Exercise and Breast Cancer Risk

Diabetes Mellitus and Risk of Colorectal Cancer

Deguelin and Tobacco-Induced Lung Tumorigenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?